Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue rose 30% to $1.7 billion and GAAP EPS increased 144% to $2.05. Recent FDA approval of a TEVIMBRA-based regimen and positive Phase 3 MANGROVE results provide fresh catalysts; shares were up 15.7% through August 27.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Positive Cash Flow ⢠High Valuation ONC has exceptional liquidity, strong margins, and positive cash flow with declining leverage, but its expensive valuation, weak annual returns, heavy R&D spending, retained losses, and lack of shareholder distributions create significant investment risks.
Price Behavior
Key Price Behavior Insights: ⢠Higher-Low Momentum ⢠Resistance Hesitation ⢠Pullback Risk Support Level: $359â362, $347â350, $329â330 Resistance Level: $376.86 ONC rose 14.6% last month with strong higher-low momentum, but hesitation below $376.86 raises near-term pullback risk toward $359â362.
Sentiment & News
Key News Insights: ⢠Strong Q2 Growth ⢠Strategic Partnerships ⢠Expanded Global Access BeOne Medicines delivered strong Q2 growth driven by BRUKINSA, while expanding investor support, partnerships, and global patient access.
AI Summary
ONC has evolved into a cash-generating commercial oncology platform, but its premium valuation leaves limited room for error, making sustained BRUKINSA growth, margin expansion, and credible pipeline diversification the key signals to monitor.
Description
BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops and commercializes cancer therapies. Headquartered in Cambridge, Massachusetts and redomiciled to Basel in 2025, the firm operates in over 45 countries and maintains a pipeline across hematologic malignancies and solid tumors sourced from internal R&D and external collaborations. Its marketed medicines include the PD-1 antibody Tevimbra (tislelizumab) and the BTK inhibitor Brukinsa (zanubrutinib), the latter generating more than $1.3 billion in annual sales and approved in major markets.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 27 | Sep 3 | ONC | BeOne Medicines Ltd. | Q2 revenue rose 30% to $1.7 billion and GAAP EPS increased 144% to $2.05. Recent FDA approval of a TEVIMBRA-based regimen and positive Phase 3 MANGROVE results provide fresh catalysts; shares were up 15.7% through August 27. | Active | +0.0% |